The relevance of CD39 and CD73 in modulating ATP and ADO levels in the TME also comes from the observation that cancer cell lines, immune cells, and stromal cells express these enzymes, and then they may be considered immune checkpoints in cancer [130]. This evidence concerns the gene ENTPD1 and cancer.